Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. ESBL-production in Escherichia coli and Klebsiella pneumoniae isolates from Nigeria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A mariner transposon vector adapted for mutagenesis in oral streptococci

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Genome Sequence of an Unknown Subtype of Hepatitis C Virus Genotype 6: Another Piece for the Taxonomic Puzzle

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. LISTERIA MENINGITIS IN DANISH CHILDREN 2000-2017: A Rare Event Even in a Country With High Rates of Invasive Listeriosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. ESBL-production in Escherichia coli and Klebsiella pneumoniae isolates from Nigeria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Pivmecillinam (amdinocillin pivoxil) is the recommended first-choice antibiotic used to treat urinary tract infections (UTIs) in Denmark. The frequency of mutation to mecillinam (MEC) resistance is described as high in vitro; however, treatment of UTI has a good clinical response and prevalence of mecillinam resistance in Escherichia coli remains low despite many years of use. We describe occurrence of in vivo mecillinam resistance in a clinical isolate of ESBL-producing E. coli following pivmecillinam treatment. The identified phenotypic differences in the mecillinam resistant isolate compared with the original mecillinam susceptible isolate were a full-length LPS with O-antigen (O25), mecillinam resistance and a lower MIC for ceftazidime. Regarding genotype, the resistant isolate differed with a mutation in blaCTX-M-15 to blaCTX-M-127 , loss of a part of a plasmid and a genomic island, respectively, and insertion of a transposase in wbbL, causing the rough phenotype. The observed mecillinam resistance is expected to be caused by the mutation in blaCTX-M-15 with additional contribute from the serotype shift. We continue to recommend the use of pivmecillinam as first-line treatment for UTI.

OriginalsprogEngelsk
TidsskriftMicrobiologyOpen
ISSN2045-8827
DOI
StatusE-pub ahead of print - 1 okt. 2019

Bibliografisk note

© 2019 The Authors. MicrobiologyOpen published by John Wiley & Sons Ltd.

ID: 58060601